Science

Diego Díaz García: EGFR TKIs now cover early-stage and locally advanced disease

Diego Díaz García/X

Mar 15, 2025, 12:28

Diego Díaz García: EGFR TKIs now cover early-stage and locally advanced disease

Diego Díaz García, Medical Oncologist, CEO and Founder of CánCare, shared a post on X about a paper by Fei Zhou et al. published in Nature Reviews Clinical Oncology:

“EGFR-mutant NSCLC is evolving.

EGFR TKIs now cover early-stage and locally advanced disease, a milestone in precision oncology.

New combos with anti-angiogenics, chemo, ADCs and bispecifics aim to boost OS.”

“The changing treatment landscape of EGFR-mutant non-small-cell lung cancer”

Authors: Fei Zhou, Haoyue Guo, Yang Xia, Xiuning Le, Daniel Tan, Suresh Ramalingam and Caicun Zhou.

Diego Díaz García: EGFR TKIs now cover early-stage and locally advanced disease

More posts featuring Diego Díaz García.

Caicun Zhou cancer Daniel Tan Diego Díaz García EGFR TKIs Fei Zhou Haoyue Guo NSCLC OncoDaily Oncology Precision Oncology Suresh Ramalingam Xiuning Le Yang Xia

Audrey Evans - mother of neuroblastoma, a force for good in the world

New Paper Alert: Management of Immune Checkpoint Inhibitor-Associated Toxicities in Older Adults with Cancer

Kimryn Rathmell was Awarded 2025 ACS Medal of Honor

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

Special Coverage